The House Appropriations Subcommittee on Labor, Health and Human Services, and Education today approved by voice vote legislation that would provide $177.1 billion in discretionary funding for the departments of Labor, HHS and Education in fiscal year 2019. According to a committee summary, the bill would provide $89.2 billion for HHS, $1 billion more than this year and $2.4 billion more than the president’s budget request. Specific increases include $1.25 billion more for the National Institutes of Health; $860 million more for the Public Health and Social Services Emergency Fund, including a $15 million increase for Hospital Preparedness Program grants; and $448 million more for the Substance Abuse and Mental Health Services Administration, including a $36 million increase to address opioid and other substance use disorders. The bill would reduce funding for the Centers for Disease Control and Prevention by $663 million, Health Resources and Services Administration by $196 million, and Centers for Medicare & Medicaid Services by $168 million, while HRSA’s Children’s Hospitals Graduate Medical Education program would receive a $10 million increase. The full committee could mark up the bill as early as next week.

Headline
In this conversation, three leaders from CommonSpirit Health explore how the organization is confronting stigma about substance use head-on through education,…
Headline
The Health Resources and Services Administration will award grants to rural hospitals and other providers from two areas of its Rural Communities Opioid…
Perspective
Public
May is Mental Health Awareness Month, a time to elevate a conversation that hospitals and health systems live every day. Behavioral health is inseparable from…
Headline
The AHA April 29 urged House and Senate appropriations committee leaders to fund health care programs that have been successful in improving access to care for…
Headline
The AHA submitted a statement for the record to the House Ways and Means Committee for its April 28 hearing with health system CEOs.In the statement, the AHA…
Headline
The Food and Drug Administration today announced it is accelerating regulatory action on a new class of psychedelic-based therapies, following an April 18…